Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India
*Corresponding Author E-mail: keerthi.sps@velsuniv.ac.in
Online published on 20 May, 2025.
Drugs with shorter half-life administered to patients get easily cleared from the body, which makes frequent administration of the drugs necessary. This makes patient compliance an important factor that determines the efficiency of treatment. Sustained release of drugs on demand is still a challenge in the field of drug delivery that motivated us to work towards designing a simple system that can help to achieve a sustained release of drug from nanoparticles.
Mefenamic acid and Mosapride were made into nanoparticles using hot homogenization technique and characterized. In-vitro drug release of conventional dosage form and nanoparticles were performed.
The Mefenamic acid and Mosapride nanoparticles obtained proved a Particle size of 180nm and 190nm respectively. Zeta potential was observed to be -25 mV and -28 mV. TEM proved that the nanoparticles were of spherical in shape. In-vitro drug release profile showed a significant drug release in nanoparticle when compared with the marketed formulation.
These works contribute to improve Mefenamic acid and Mosapride clinical use, and further develop drug carriers for achieving sustained and controlled the release of the drugs in demand.
Mefenamic acid, Mosapride, Sustained release, In-vitro drug release, Solid lipid nanoparticles
